曲妥珠-话题@MedSci

#曲妥珠#

132篇内容 | 3556人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1648145, encodeId=d747164814549, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=抗体-药物偶联物（曲妥珠单抗-deruxtecan）治疗早期乳腺癌, objectType=article, longId=167058, objectId=b1f316e058d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1f316e058d6, replyNumber=0, likeNumber=73, createdTime=2020-01-19, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1f316e058d6, moduleTitle=抗体-药物偶联物（曲妥珠单抗-deruxtecan）治疗早期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b1f316e058d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648144, encodeId=c838164814414, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=加拿大卫生部批准**款曲妥珠单抗生物仿制药Ogivri用于治疗HER2阳性的乳腺癌和胃癌, objectType=article, longId=166718, objectId=55b4166e1844, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55b4166e1844, replyNumber=0, likeNumber=78, createdTime=2020-04-29, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55b4166e1844, moduleTitle=加拿大卫生部批准**款曲妥珠单抗生物仿制药Ogivri用于治疗HER2阳性的乳腺癌和胃癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55b4166e1844)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648140, encodeId=12b01648140ba, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=FDA批准曲妥珠单抗生物类似物Herzuma（曲妥珠单抗-pkrb）, objectType=article, longId=155932, objectId=d125155932ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d125155932ad, replyNumber=0, likeNumber=130, createdTime=2019-02-26, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d125155932ad, moduleTitle=FDA批准曲妥珠单抗生物类似物Herzuma（曲妥珠单抗-pkrb）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d125155932ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648134, encodeId=8c8816481345f, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=CHMP对Mylan和Biocon的曲妥珠单抗生物类似物Ogivri持积极意见, objectType=article, longId=151532, objectId=0831151532cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0831151532cc, replyNumber=0, likeNumber=93, createdTime=2019-04-07, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0831151532cc, moduleTitle=CHMP对Mylan和Biocon的曲妥珠单抗生物类似物Ogivri持积极意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0831151532cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648141, encodeId=0438164814133, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=曲妥珠单抗多线治疗HER2阳性型晚期乳腺癌1例, objectType=article, longId=156798, objectId=ca5a156e98dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca5a156e98dd, replyNumber=0, likeNumber=0, createdTime=2019-02-26, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca5a156e98dd, moduleTitle=曲妥珠单抗多线治疗HER2阳性型晚期乳腺癌1例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca5a156e98dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648148, encodeId=94f116481484b, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=ASCO2019 |帕妥珠单抗、曲妥珠单抗和多西紫杉醇联合一线治疗her2阳性转移性乳腺癌的中国桥接研究（PUFFIN）, objectType=article, longId=167604, objectId=9de016e60451, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9de016e60451, replyNumber=0, likeNumber=90, createdTime=2019-06-22, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9de016e60451, moduleTitle=ASCO2019 |帕妥珠单抗、曲妥珠单抗和多西紫杉醇联合一线治疗her2阳性转移性乳腺癌的中国桥接研究（PUFFIN）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9de016e60451)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648128, encodeId=698a164812883, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=JAHA：曲妥珠单抗能否用于射血分数降低的乳腺癌患者？, objectType=article, longId=145188, objectId=91841451884b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91841451884b, replyNumber=0, likeNumber=65, createdTime=2019-02-16, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91841451884b, moduleTitle=JAHA：曲妥珠单抗能否用于射血分数降低的乳腺癌患者？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=91841451884b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648138, encodeId=33511648138a5, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=JCO：曲妥珠单抗联合多西紫杉醇治疗晚期涎腺导管癌, objectType=article, longId=154708, objectId=3432154e08da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3432154e08da, replyNumber=0, likeNumber=94, createdTime=2018-12-11, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3432154e08da, moduleTitle=JCO：曲妥珠单抗联合多西紫杉醇治疗晚期涎腺导管癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3432154e08da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648130, encodeId=1ffe1648130bd, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Lancet Oncol：曲妥珠单抗+帕妥珠单抗+化疗不能延长HER2阳性转移性胃或胃食管交界癌患者总生存期, objectType=article, longId=148716, objectId=1eac148e167e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1eac148e167e, replyNumber=0, likeNumber=56, createdTime=2019-03-11, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1eac148e167e, moduleTitle=Lancet Oncol：曲妥珠单抗+帕妥珠单抗+化疗不能延长HER2阳性转移性胃或胃食管交界癌患者总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1eac148e167e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648135, encodeId=8395164813501, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=J Gastroenterology：HER2变异会对HER2阳性胃癌患者接受曲妥珠单抗疗效产生影响, objectType=article, longId=153292, objectId=0cc015329201, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0cc015329201, replyNumber=0, likeNumber=0, createdTime=2018-11-15, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0cc015329201, moduleTitle=J Gastroenterology：HER2变异会对HER2阳性胃癌患者接受曲妥珠单抗疗效产生影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0cc015329201)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648136, encodeId=7e001648136a6, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=曲妥珠单抗治疗进展后再使用病例, objectType=article, longId=153590, objectId=748a153590a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=748a153590a8, replyNumber=0, likeNumber=75, createdTime=2019-09-28, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=748a153590a8, moduleTitle=曲妥珠单抗治疗进展后再使用病例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=748a153590a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648137, encodeId=8ed6164813ee1, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=美例秀秀｜曲妥珠单抗治疗进展后何去何从？, objectType=article, longId=154237, objectId=8caf15423e69, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8caf15423e69, replyNumber=0, likeNumber=99, createdTime=2018-12-14, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8caf15423e69, moduleTitle=美例秀秀｜曲妥珠单抗治疗进展后何去何从？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8caf15423e69)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648132, encodeId=973316481325e, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=GUT：HER2阳性转移性胃癌患者曲妥珠单抗耐药机制研究进展, objectType=article, longId=150583, objectId=c84815058345, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c84815058345, replyNumber=0, likeNumber=67, createdTime=2019-07-11, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c84815058345, moduleTitle=GUT：HER2阳性转移性胃癌患者曲妥珠单抗耐药机制研究进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c84815058345)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648119, encodeId=844f164811952, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=EUR J Cancer：一项比较SB3（曲妥珠单抗生物类似物）和曲妥珠单抗的III期临床研究, objectType=article, longId=130729, objectId=edaa130e2993, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edaa130e2993, replyNumber=0, likeNumber=58, createdTime=2018-03-18, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edaa130e2993, moduleTitle=EUR J Cancer：一项比较SB3（曲妥珠单抗生物类似物）和曲妥珠单抗的III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=edaa130e2993)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648127, encodeId=99f3164812eff, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Lancet oncol：ABP980，曲妥珠单抗的生物类似物，用于HER2阳性的乳腺癌患者的效果和安全性，与曲妥珠单抗的不相上下, objectType=article, longId=140064, objectId=732314006499, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=732314006499, replyNumber=0, likeNumber=72, createdTime=2019-04-18, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=732314006499, moduleTitle=Lancet oncol：ABP980，曲妥珠单抗的生物类似物，用于HER2阳性的乳腺癌患者的效果和安全性，与曲妥珠单抗的不相上下, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=732314006499)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648122, encodeId=929316481228c, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=JCO：HER2阳性乳腺癌患者新辅助化疗联合曲妥珠单抗或拉帕替尼治疗后生存分析, objectType=article, longId=132605, objectId=9efd13260523, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9efd13260523, replyNumber=0, likeNumber=73, createdTime=2018-08-25, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9efd13260523, moduleTitle=JCO：HER2阳性乳腺癌患者新辅助化疗联合曲妥珠单抗或拉帕替尼治疗后生存分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9efd13260523)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648139, encodeId=3ae116481394a, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=帕妥珠单抗+曲妥珠单抗双靶新辅助治疗HER2阳性乳腺癌, objectType=article, longId=154864, objectId=cab015486477, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cab015486477, replyNumber=0, likeNumber=116, createdTime=2018-12-28, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cab015486477, moduleTitle=帕妥珠单抗+曲妥珠单抗双靶新辅助治疗HER2阳性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cab015486477)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648126, encodeId=314d1648126e2, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Lancet oncol：Tucatinib联合卡培他滨、曲妥珠单抗治疗HER2阳性的进展期乳腺癌患者，毒副作用可接受，且具有抗肿瘤效果, objectType=article, longId=139112, objectId=33c3139112e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33c3139112e3, replyNumber=0, likeNumber=61, createdTime=2018-10-11, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33c3139112e3, moduleTitle=Lancet oncol：Tucatinib联合卡培他滨、曲妥珠单抗治疗HER2阳性的进展期乳腺癌患者，毒副作用可接受，且具有抗肿瘤效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33c3139112e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648124, encodeId=2eba16481248e, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=HER2阳性乳腺癌性脑膜炎患者鞘内注射曲妥珠单抗的可行性研究, objectType=article, longId=136866, objectId=9bc413686612, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9bc413686612, replyNumber=0, likeNumber=81, createdTime=2018-08-29, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9bc413686612, moduleTitle=HER2阳性乳腺癌性脑膜炎患者鞘内注射曲妥珠单抗的可行性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9bc413686612)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648133, encodeId=3929164813387, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=HER2阳性乳腺癌患者可能受益于短程曲妥珠单抗疗法, objectType=article, longId=151496, objectId=80e315149618, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80e315149618, replyNumber=0, likeNumber=0, createdTime=2019-03-28, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80e315149618, moduleTitle=HER2阳性乳腺癌患者可能受益于短程曲妥珠单抗疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=80e315149618)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

曲妥珠

2020-05-29

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

抗体-药物偶联物（曲妥珠单抗-deruxtecan）治疗早期乳腺癌

2020-01-19

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

加拿大卫生部批准**款曲妥珠单抗生物仿制药Ogivri用于治疗HER2阳性的乳腺癌和胃癌

2020-04-29

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

FDA批准曲妥珠单抗生物类似物Herzuma（曲妥珠单抗-pkrb）

2019-02-26

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

CHMP对Mylan和Biocon的曲妥珠单抗生物类似物Ogivri持积极意见

2019-04-07

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

曲妥珠单抗多线治疗HER2阳性型晚期乳腺癌1例

2019-02-26

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

ASCO2019 |帕妥珠单抗、曲妥珠单抗和多西紫杉醇联合一线治疗her2阳性转移性乳腺癌的中国桥接研究（PUFFIN）

2019-06-22

仁心济世 (审核中...)

前往app查看评论内容

#曲妥珠#

JAHA：曲妥珠单抗能否用于射血分数降低的乳腺癌患者？

2019-02-16

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

JCO：曲妥珠单抗联合多西紫杉醇治疗晚期涎腺导管癌

2018-12-11

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Lancet Oncol：曲妥珠单抗+帕妥珠单抗+化疗不能延长HER2阳性转移性胃或胃食管交界癌患者总生存期

2019-03-11

zhaojie88 (审核中...)

前往app查看评论内容

#曲妥珠#

J Gastroenterology：HER2变异会对HER2阳性胃癌患者接受曲妥珠单抗疗效产生影响

2018-11-15

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

曲妥珠单抗治疗进展后再使用病例

2019-09-28

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

美例秀秀｜曲妥珠单抗治疗进展后何去何从？

2018-12-14

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

GUT：HER2阳性转移性胃癌患者曲妥珠单抗耐药机制研究进展

2019-07-11

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

EUR J Cancer：一项比较SB3（曲妥珠单抗生物类似物）和曲妥珠单抗的III期临床研究

2018-03-18

仁心济世 (审核中...)

前往app查看评论内容

#曲妥珠#

Lancet oncol：ABP980，曲妥珠单抗的生物类似物，用于HER2阳性的乳腺癌患者的效果和安全性，与曲妥珠单抗的不相上下

2019-04-18

仁心济世 (审核中...)

前往app查看评论内容

#曲妥珠#

JCO：HER2阳性乳腺癌患者新辅助化疗联合曲妥珠单抗或拉帕替尼治疗后生存分析

2018-08-25

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

帕妥珠单抗+曲妥珠单抗双靶新辅助治疗HER2阳性乳腺癌

2018-12-28

仁心济世 (审核中...)

前往app查看评论内容

#曲妥珠#

Lancet oncol：Tucatinib联合卡培他滨、曲妥珠单抗治疗HER2阳性的进展期乳腺癌患者，毒副作用可接受，且具有抗肿瘤效果

2018-10-11

仁心济世 (审核中...)

前往app查看评论内容

#曲妥珠#

HER2阳性乳腺癌性脑膜炎患者鞘内注射曲妥珠单抗的可行性研究

2018-08-29

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

HER2阳性乳腺癌患者可能受益于短程曲妥珠单抗疗法

2019-03-28

科室
- - 订阅+
  - 更多科室
工具
服务